Myovant Sciences Cancels Second Quarter Earnings Conference Call

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) has canceled its earnings conference call for Q3 2022, originally scheduled for October 26, 2022. The cancellation is due to the upcoming merger with Sumitovant Biopharma Ltd., Myovant's majority shareholder. Founded in 2016, Myovant focuses on hormone-sensitive oncology and women's health, having successfully completed five Phase 3 clinical trials leading to multiple regulatory approvals in the U.S. and Europe. The company aims to further develop additional indications and pipeline assets.

Positive

• Successful completion of five Phase 3 clinical trials.
• Multiple regulatory approvals in the U.S. and Europe.

Negative

• Cancellation of Q3 earnings call may indicate uncertainty or shift focus due to merger.

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.

ABOUT MYOVANT SCIENCES

Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and women’s health leading to five regulatory approvals in the United States and Europe. Myovant and its partners continue to file for additional indications of its lead products as well as continue further development of pipeline assets. Sumitovant Biopharma Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com.

Investor Contact:
Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.
investors@myovant.com 

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communication
Myovant Sciences, Inc.
media@myovant.com

 

FAQ

Why was the Myovant Sciences Q3 earnings call canceled?

The earnings call was canceled due to the announcement of a pending merger with Sumitovant Biopharma Ltd.

What are the implications of Myovant Sciences merging with Sumitovant Biopharma?

The merger could streamline operations and enhance product development, but it may also introduce uncertainty during the transition.

What are Myovant Sciences' recent achievements in clinical trials?

Myovant has successfully executed five Phase 3 clinical trials, resulting in multiple regulatory approvals.

How might the merger affect Myovant Sciences' future goals?

The merger is expected to support Myovant's strategic goals and expansion of its product pipeline.